Precision gene editing could prevent vision loss from Stargardt disease
Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...
AZoLifeSciences on MSN1d
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
Rewriting genes to preserve eyesight IOB and Beam Therapeutics develop efficient gene editing technique for Stargardt disease ...
GEN1d
Base Editing Addresses Inherited Macular Degeneration in Primate, Human Tissue Models
The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today ...
Institute of Molecular and Clinical Ophthalmology Basel (IOB): Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, pu ...
BreakingNews.ie4d
Sisters to highlight rare eye condition at BT science exhibition
Caitlin and Caoimhe Mynes stole the hearts of viewers when they had the craic with Ryan Tubridy making lava lamps and glitter ...
Mena FN23d
Stargardt Disease Market Poised For Significant Growth From 2024 To 2034, Reports Delveinsight
Stargardt Disease Market Forecast-2034 report offers an in-depth understanding of the forecasted epidemiology as well as the market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, December 19 ...
The Globe and Mail19d
Stargardt Disease Therapeutics Market Size in the 7MM was ~USD 27 million in 2023, which is expected to increase by 2034, estimated DelveInsight
DelveInsight’s “Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted ...
Healio19d
FDA clears investigational new drug application for Stargardt disease gene therapy
Please provide your email address to receive an email when new articles are posted on . A phase 1/2 trial will assess safety, tolerability and preliminary efficacy for VG801. The FDA also selected ...
Pharmaceutical Technology12d
ACDN-01 by Ascidian Therapeutics for Retinopathy: Likelihood of Approval
ACDN-01 is under clinical development by Ascidian Therapeutics and currently in Phase II for Retinopathy. According to GlobalData, Phase II drugs for Retinopathy have a 51% phase transition success ...